The future of drug discovery.

We an artificial intelligence-driven techbio start-up that specialises in antibody design against challenging targets, including G-protein coupled receptors (GPCRs) and ion channels. Headquartered in Cardiff, UK and with offices in Boston, MA, we combine state-of-the-art machine learning techniques and advanced cell line engineering to develop de novo antibody therapeutics.

We believe a better-connected community will form the foundations for the future of drug discovery. In addition to our other media streams, including the Future of Drug Discovery podcast, we hope to provide resources for the AI drug discovery industry to accelerate towards a disease-free world. We hope to catalyse the next generation of innovative treatments through collaboration.

We post updates on our progress, press releases and articles monthly.

Subscribe to Updates at Antiverse!

About Antiverse

To learn more about Antiverse, you can visit our website, or check us out on LinkedIn and Twitter.

Subscribe to Updates at Antiverse

Engineering the future of drug discovery. Antiverse's media platform for all the latest updates.


Engineering the future of drug discovery